Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/B8d257f0f4aae5555190db31f94ea3ed6> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- B8d257f0f4aae5555190db31f94ea3ed6 NCIT_P378 "NCI" @default.
- B8d257f0f4aae5555190db31f94ea3ed6 type Axiom @default.
- B8d257f0f4aae5555190db31f94ea3ed6 annotatedProperty IAO_0000115 @default.
- B8d257f0f4aae5555190db31f94ea3ed6 annotatedSource NCIT_C52200 @default.
- B8d257f0f4aae5555190db31f94ea3ed6 annotatedTarget "An orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Cabozantinib strongly binds to and inhibits several RTKs, which are often overexpressed in a variety of cancer cell types, including hepatocyte growth factor receptor (MET), RET (rearranged during transfection), vascular endothelial growth factor receptor types 1 (VEGFR-1), 2 (VEGFR-2), and 3 (VEGFR-3), mast/stem cell growth factor (KIT), FMS-like tyrosine kinase 3 (FLT-3), TIE-2 (TEK tyrosine kinase, endothelial), tropomyosin-related kinase B (TRKB) and AXL. This may result in an inhibition of both tumor growth and angiogenesis, and eventually lead to tumor regression." @default.